High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.

The concepts of high-throughput (HT) screening and combinatorial synthesis have been integrated into the pharmaceutical discovery process, but are not yet commonplace in the pharmaceutical development arena. Emerging strategies to speed pharmaceutical development and capture solid form diversity of pharmaceutical substances have resulted in the emergence of HT crystallization technologies. The primary type of diversity often refers to polymorphs, which are different crystal forms of the same chemical composition. However, diverse salt forms, co-crystals, hydrates and solvates are also amenable to study in HT crystallization systems. The impact of form diversity encompasses issues of stability and bioavailability, as well as development considerations such as process definition, formulation design, patent protection and regulatory control. This review highlights the opportunities and challenges of HT crystallization technologies as they apply to pharmaceutical research and development.

[1]  F. Leusen.  Crystal Structure Prediction of Diastereomeric Salts: A Step toward Rationalization of Racemate Resolution , 2003 .

[2]  G A Stephenson,et al.  Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.

[3]  R. Davey,et al.  From Molecules to Crystallizers , 2001 .

[4]  Jonathan Harr,et al.  A Civil Action , 1995 .

[5]  Gordon J. T. Tiddy,et al.  Crystal engineering – nucleation, the key step , 2002 .

[6]  D. Allan,et al.  The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors. , 2002, Acta crystallographica. Section B, Structural science.

[7]  Jack,et al.  Disappearing Polymorphs , 2001 .

[8]  W. Tong,et al.  In situ salt screening--a useful technique for discovery support and preformulation studies. , 1998, Pharmaceutical development and technology.

[9]  L. Blair.  A prediction. , 1995, Hospitals & health networks.

[10]  Kenneth R. Morris,et al.  An integrated approach to the selection of optimal salt form for a new drug candidate , 1994 .

[11]  D. Bugay.  Characterization of the solid-state: spectroscopic techniques. , 2001, Advanced drug delivery reviews.

[12]  J. Guillory.  GENERATION OF POLYMORPHS, HYDRATES, SOLVATES, AND AMORPHOUS SOLIDS , 1999 .

[13]  Matt Peterson,et al.  Application of high throughput technologies to drug substance and drug product development , 2004, Comput. Chem. Eng..

[14]  Stephen Byrn,et al.  Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.

[15]  A. Myerson,et al.  Effect of Additives on the Transformation Behavior of l-Phenylalanine in Aqueous Solution , 2001 .

[16]  W. Beckmann,et al.  Crystallisation of the Stable Polymorph of Hydroxytriendione: Seeding Process and Effects of Purity , 2001 .

[17]  S. Byrn.  Solid state chemistry of drugs , 1982 .

[18]  A. Matzger,et al.  The use of polymer heteronuclei for crystalline polymorph selection. , 2002, Journal of the American Chemical Society.

[19]  C. A. Mitchell,et al.  Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. , 2001, Journal of the American Chemical Society.

[20]  Lian Yu.  Color Changes Caused by Conformational Polymorphism: Optical-Crystallography, Single-Crystal Spectroscopy, and Computational Chemistry , 2002 .

[21]  L. Leiserowitz,et al.  The effect of solvent on crystal growth and morphology , 2001 .

[22]  S M Berge,et al.  Pharmaceutical salts. , 1977, Journal of pharmaceutical sciences.

[23]  R. J. Roberts,et al.  Potential polymorphs of aspirin , 1999, J. Comput. Chem..

[24]  T. Threlfall.  Crystallisation of Polymorphs: Thermodynamic Insight into the Role of Solvent , 2000 .

[25]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[26]  Thomas D.Y. Chung,et al.  Assay Miniaturization for Ultra-High Throughput Screening of Combinatorial and Discrete Compound Libraries: A 9600-Well (0.2 Microliter) Assay System , 1998 .

[27]  J. McMahon,et al.  Crystal engineering of the composition of pharmaceutical phases. , 2003, Chemical communications.

[28]  Crystalline Solids , 2018, Statistical Thermodynamics.

[29]  David J.W. Grant,et al.  Solid-state pharmaceutical chemistry , 1994 .

[30]  A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal , 2003 .

[31]  H. Brittain.  Polymorphism in Pharmaceutical Solids , 1999 .

[32]  J. Anwar,et al.  Crystallization of polymorphs : the effect of solvent , 1993 .

[33]  P Verwer,et al.  A test of crystal structure prediction of small organic molecules. , 2000, Acta crystallographica. Section B, Structural science.

[34]  J. Dunitz.  Are crystal structures predictable? , 2003, Chemical communications.

[35]  C. A. Mitchell,et al.  Thermochemistry and Conformational Polymorphism of a Hexamorphic Crystal System , 2000 .

[36]  R. Davey,et al.  Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole , 1998 .

[37]  L. Addadi,et al.  Molecular Recognition at Crystal Interfaces , 1991, Science.

[38]  P. L. Gould,et al.  Salt selection for basic drugs , 1986 .

[39]  Sarah L Price,et al.  Crystal structure prediction of small organic molecules: a second blind test. , 2002, Acta crystallographica. Section B, Structural science.

[40]  Orn Almarsson,et al.  High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds , 2003 .

[41]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[42]  A. Myerson,et al.  Polarization switching of crystal structure in the nonphotochemical light-induced nucleation of supersaturated aqueous glycine solutions. , 2002, Physical review letters.

[43]  J. Bernstein.  Crystal growth, polymorphism and structure-property relationships in organic crystals , 1993 .

[44]  A. Gavezzotti,et al.  Ten years of experience in polymorph prediction: what next? , 2002 .

[45]  Jeffrey S. Tan,et al.  Capillary Precipitation of a Highly Polymorphic Organic Compound , 2003 .

[46]  E. Landau,et al.  'Tailormade' auxiliaries for nucleation, growth and dissolution of organic crystals , 1986 .

[47]  Paul E. Shaw,et al.  Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. , 2002, Journal of the American Chemical Society.

[48]  W. Ostwald.  Studien über die Bildung und Umwandlung fester Körper , 1897 .

[49]  George Zhou,et al.  Process Optimization of a Complex Pharmaceutical Polymorphic System via In Situ Raman Spectroscopy , 2002 .

[50]  Richard J. Bastin,et al.  Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities , 2000 .

[51]  Thomas Earnest,et al.  Automation of X-ray crystallography , 2000, Nature Structural Biology.

[52]  S. Tavener,et al.  Sulfathiazole polymorphism studied by magic-angle spinning NMR. , 1999, Journal of pharmaceutical sciences.

[53]  D. Fox.  Physics and Chemistry of the Organic Solid State , 1963 .

[54]  P. Cong,et al.  High throughput screening techniques for pre-formulation: salt selection and polymorph studies , 2002 .

[55]  A. Gavezzotti,et al.  Are Crystal Structures Predictable , 1994 .

[56]  M. Kaufman,et al.  Investigation of the polymorphism of the angiotensin II antagonist agent MK-996. , 1999, Pharmaceutical development and technology.

[57]  R. Howie,et al.  Crystal growth , 1982, Nature.

[58]  B. A. Garetz,et al.  Nonphotochemical, laser-induced nucleation of supersaturated aqueous glycine produces unexpected γ-polymorph , 2001 .

[59]  P. York,et al.  Polymorph Control of Sulfathiazole in Supercritical CO2 , 2001, Pharmaceutical Research.

[60]  Lance Stewart,et al.  High-throughput crystallization and structure determination in drug discovery. , 2002, Drug discovery today.

[61]  Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals , 1992 .

[62]  M. Peruggia.  Experiments with Mixtures: Designs, Models, and the Analysis of Mixture Data , 2003 .

[63]  Z. Zhang,et al.  Crystal growth. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Caira,et al.  Crystalline Polymorphism of Organic Compounds , 1998 .

[65]  G. Day,et al.  The prediction, morphology, and mechanical properties of the polymorphs of paracetamol. , 2001, Journal of the American Chemical Society.

[66]  N. Rodríguez-Hornedo,et al.  Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. , 1999, Journal of pharmaceutical sciences.

[67]  I. Weissbuch,et al.  Toward Stereochemical Control, Monitoring, and Understanding of Crystal Nucleation , 2003 .

[68]  S. Chemburkar,et al.  Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .

[69]  R. Davey,et al.  Crystal Polymorphism as a Probe for Molecular Self-Assembly during Nucleation from solutions: The Case of 2,6 - Dihydroxybenzoic Acid. , 2001 .

[70]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[71]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[72]  K. Morris,et al.  Stabilization of a Metastable Polymorph of 4-Methyl-2-nitroacetanilide by Isomorphic Additives , 2001 .

[73]  B. Shekunov,et al.  Formation of composite crystals by precipitation in supercritical CO2 , 2003 .

[74]  I. Hunter,et al.  Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes. , 2003, Journal of pharmaceutical sciences.

[75]  S. Childs,et al.  Polymorph Generation in Capillary Spaces: The Preparation and Structural Analysis of a Metastable Polymorph of Nabumetone , 2002 .

[76]  R. Docherty,et al.  Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry , 1997 .

[77]  J. Cornell.  Experiments with Mixtures: Designs, Models and the Analysis of Mixture Data , 1982 .

[78]  Young,et al.  Nonphotochemical, Polarization-Dependent, Laser-Induced Nucleation in Supersaturated Aqueous Urea Solutions. , 1996, Physical review letters.

[79]  Can crystal structure prediction be used as part of an integrated strategy for ensuring maximum diversity of isolated crystal forms? The case of 2-amino-4-nitrophenol , 2001 .

[80]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .

[81]  A. Matzger,et al.  Form IV of carbamazepine. , 2002, Journal of pharmaceutical sciences.

[82]  Michael J. Cima,et al.  Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. S. Payne,et al.  Crystal chemistry and solvent effects in polymorphic systems Sulfathiazole , 1998 .